Publications

Most Recent:

Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA, Infectious Diseases Society of America . Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 Jan; 58(1).

Mercer F, Khaitan A, Kozhaya L, Aberg JA, Unutmaz D. Differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors. Journal of immunology (Baltimore, Md. : 1950) 2014 Aug; 193(3).

Cespedes MS, Castor D, Ford SL, Lee D, Lou Y, Pakes GE, Aberg JA. Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy. Journal of acquired immune deficiency syndromes (1999) 2013 Apr; 62(5).

Cespedes MS, Kerns SL, Holzman RS, McLaren PJ, Ostrer H, Aberg JA. Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268. HIV clinical trials; 14(6).

O’Brien M, Montenont E, Hu L, Nardi MA, Valdes V, Merolla M, Gettenberg G, Cavanagh K, Aberg JA, Bhardwaj N, Berger JS. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. Journal of acquired immune deficiency syndromes (1999) 2013 Jul; 63(3).

Wolff MJ, Poles MA, Aberg JA. Clash of the microbes: let’s bring back the good guys. The Journal of clinical investigation 2013 Feb; 123(2).

Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, Falcon R, Ryan R, De La Rosa G. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS research and human retroviruses 2012 Oct; 28(10).

Aberg JA. Aging, inflammation, and HIV infection. Topics in antiviral medicine; 20(3).

Doshi S, Chen TF, Zapata J, Holzman RS, Zapata LC, Aberg JA, Sivapalasingam S. Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2012 Jul; 16(7).

Doshi S, Chen TF, Zapata J, Holzman RS, Zapata LC, Aberg JA, Sivapalasingam S. Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2012 Jul; 16(7).

Eckhardt BJ, Holzman RS, Kwan CK, Baghdadi J, Aberg JA. Glycated Hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals. AIDS patient care and STDs 2012 Apr; 26(4).

Kwan CK, Eckhardt B, Baghdadi J, Aberg JA. Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. AIDS research and human retroviruses 2012 Sep; 28(9).

Danoff A, Daskalakis D, Aberg JA. Care for transgender persons. JAMA 2013 May; 309(20).

Danoff A, Horberg M, Aberg JA. Reply to Monroe and Brown. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2014 Jun; 58(11).

Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, G√ľnthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012 Jul; 308(4).

Anthony DD, Umbleja T, Aberg JA, Kang M, Medvik K, Lederman MM, Peters MG, Koziel MJ, Overton ET. Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals. Vaccine 2011 Apr; 29(19).

Bakare N, Edwards IR, Stergachis A, Pal S, Holmes CB, Lindquist M, Duncombe C, Dodoo A, Novendstern J, Nwokike J, Kuchenbecker R, Aberg JA, Miller V, Strobos J. Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities. PLoS medicine 2011 Jul; 8(7).

DallaPiazza M, Aberg JA. HIV counseling and testing for household members of HIV-infected individuals in Africa: should prevention programs focus on home-based rather than clinic-based outreach?. Current HIV/AIDS reports 2011 Jun; 8(2).

Engell CA, Pham VP, Holzman RS, Aberg JA. Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients. ISRN gastroenterology 2011; 2011.

Fichtenbaum CJ, Evans SE, Aberg JA. High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection. AIDS (London, England) 2011 Oct; 25(16).

Malvestutto CD, Aberg JA. Management of dyslipidemia in HIV-infected patients. Clinical lipidology 2011 Aug; 6(4).

Mehta SA, Silvera R, Bernstein K, Holzman RS, Aberg JA, Daskalakis DC. Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City. Sexually transmitted infections 2011 Jun; 87(4).

Overton ET, Sungkanuparph S, Klebert M, Royal M, Demarco-Shaw D, Powderly WG, Aberg JA. GM-CSF Fails to Improve Immune Responses to Booster Hepatitis B Vaccination in HIV-Infected Individuals. The open virology journal 2011; 5.

Squires KE, Hodder SL, Feinberg J, Bridge DA, Abrams S, Storfer SP, Aberg JA. Health needs of HIV-infected women in the United States: insights from the women living positive survey. AIDS patient care and STDs 2011 May; 25(5).